A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in Mice

A Fusion Protein Vaccine Containing OprF Epitope 8, OprI, and Type A and B Flagellins Promotes Enhanced Clearance of Nonmucoid Pseudomonas aeruginosa

(2009) E. T. Weimer et al.   INFECTION AND IMMUNITY

Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin

(2009) J. T. Bates et al.   JOURNAL OF IMMUNOLOGY

Immunization of young African green monkeys with OprF epitope 8–OprI–type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonasaeruginosa

(2009) Eric T. Weimer et al.   VACCINE

Flagellin-F1-V Fusion Protein Is an Effective Plague Vaccine in Mice and Two Species of Nonhuman Primates

(2008) S. B. Mizel et al.   Clinical and Vaccine Immunology

Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge

(2008) A. Berhanu et al.   JOURNAL OF VIROLOGY

Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement

(2008) M. R.-E.-I. Benhnia et al.   JOURNAL OF VIROLOGY

Mucosal adjuvant activity of flagellin in aged mice

(2008) John T. Bates et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

(2007) James W. Huleatt et al.   VACCINE